|
ATE395083T1
(de)
|
2003-11-21 |
2008-05-15 |
Ucb Pharma Sa |
Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität
|
|
CN101326195B9
(zh)
*
|
2005-12-13 |
2022-11-11 |
伊莱利利公司 |
抗il-17抗体
|
|
US7910703B2
(en)
|
2006-03-10 |
2011-03-22 |
Zymogenetics, Inc. |
Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
|
|
WO2007106769A2
(en)
|
2006-03-10 |
2007-09-20 |
Zymogenetics, Inc. |
Antibodies that bind both il-17a and il-17f and methods of using the same
|
|
US7790163B2
(en)
|
2006-03-10 |
2010-09-07 |
Zymogenetics, Inc. |
Antibodies that bind both IL-17A and IL-17F and methods of using the same
|
|
TW200815469A
(en)
*
|
2006-06-23 |
2008-04-01 |
Astrazeneca Ab |
Compounds
|
|
GB0612928D0
(en)
|
2006-06-29 |
2006-08-09 |
Ucb Sa |
Biological products
|
|
BRPI0715917A2
(pt)
|
2006-08-11 |
2014-11-25 |
Schering Corp |
Anticorpos para il-17a
|
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
|
EP3202786A3
(en)
|
2007-03-12 |
2017-10-11 |
ESBATech, an Alcon Biomedical Research Unit LLC |
Sequence based engineering and optimization of single chain antibodies
|
|
CA2689941C
(en)
*
|
2007-06-25 |
2019-10-29 |
Esbatech Ag |
Methods of modifying antibodies, and modified antibodies with improved functional properties
|
|
BRPI0813287A2
(pt)
|
2007-06-25 |
2014-12-30 |
Esbatech Alcon Biomed Res Unit |
Planejamento e otimização baseados na sequência de anticorpos de cadeia única
|
|
WO2009026412A1
(en)
*
|
2007-08-21 |
2009-02-26 |
Children's Medical Center Corporation |
Treatment of airway hyperreactivity
|
|
WO2009082624A2
(en)
*
|
2007-12-10 |
2009-07-02 |
Zymogenetics, Inc. |
Antagonists of il-17a, il-17f, and il-23 and methods of using the same
|
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
|
SG190626A1
(en)
|
2008-05-05 |
2013-06-28 |
Novimmune Sa |
Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
|
|
BRPI0919531A2
(pt)
*
|
2008-09-29 |
2015-12-08 |
Roche Glycart Ag |
anticorpos contra il17 humana e usos dos mesmos
|
|
WO2010056816A2
(en)
*
|
2008-11-12 |
2010-05-20 |
Schering Corporation |
βGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION
|
|
US8211434B2
(en)
|
2008-11-26 |
2012-07-03 |
Allergan, Inc. |
KLK-13 antibody inhibitor for treating dry eye
|
|
WO2010062858A1
(en)
*
|
2008-11-26 |
2010-06-03 |
Allergan, Inc. |
Il-17 antibody inhibitor for treating dry eye
|
|
EP2810652A3
(en)
*
|
2009-03-05 |
2015-03-11 |
AbbVie Inc. |
IL-17 binding proteins
|
|
CN102458437B
(zh)
|
2009-05-05 |
2015-06-10 |
诺维莫尼公司 |
抗il-17f抗体及其使用方法
|
|
EP2493506B1
(en)
|
2009-10-30 |
2019-04-10 |
Janssen Biotech, Inc. |
Il-17a antagonists
|
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
|
EP3372617B1
(en)
|
2010-04-02 |
2024-07-24 |
Amunix Pharmaceuticals, Inc. |
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
|
|
EP2569335B1
(en)
*
|
2010-05-14 |
2018-08-22 |
Orega Biotech |
Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
|
|
JP2013537414A
(ja)
*
|
2010-08-05 |
2013-10-03 |
アナプティスバイオ インコーポレイティッド |
Ｉｌ−１７に対する抗体
|
|
TW201302793A
(zh)
*
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
WO2012045848A1
(en)
*
|
2010-10-08 |
2012-04-12 |
Novartis Ag |
Methods of treating psoriasis using il-17 antagonists
|
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
|
PT2663577T
(pt)
|
2011-01-14 |
2017-07-19 |
Ucb Biopharma Sprl |
Anticorpo de ligação a il-17a e il-17f
|
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
|
US9943594B2
(en)
|
2011-10-11 |
2018-04-17 |
Sanofi Biotechnology |
Methods for the treatment of rheumatoid arthritis
|
|
KR20140097178A
(ko)
|
2011-11-21 |
2014-08-06 |
노파르티스 아게 |
IL-17 길항제 및 건선성 관절염 (PsA) 반응 또는 비-반응 대립유전자를 이용하여 PsA를 치료하는 방법
|
|
US9284283B2
(en)
|
2012-02-02 |
2016-03-15 |
Ensemble Therapeutics Corporation |
Macrocyclic compounds for modulating IL-17
|
|
WO2013134052A1
(en)
*
|
2012-03-07 |
2013-09-12 |
Eli Lilly And Company |
Il-17 antibody formulation
|
|
AR090626A1
(es)
|
2012-04-20 |
2014-11-26 |
Lilly Co Eli |
Anticuerpos anti-baff-anti-il-17 biespecificos
|
|
KR20150010709A
(ko)
|
2012-04-20 |
2015-01-28 |
노파르티스 아게 |
Il-17 길항제를 사용하는 강직성 척추염의 치료 방법
|
|
SI2852615T1
(sl)
|
2012-05-22 |
2019-02-28 |
Bristol-Myers Squibb Company |
IL-17A/F IL-23 bispecifična protitelesa in njihova uporaba
|
|
WO2014001368A1
(en)
|
2012-06-25 |
2014-01-03 |
Orega Biotech |
Il-17 antagonist antibodies
|
|
WO2014066726A2
(en)
|
2012-10-26 |
2014-05-01 |
Ensemble Therapeutics Corporation |
Compounds for modulating il-17
|
|
HK1215174A1
(zh)
*
|
2012-11-29 |
2016-08-19 |
Bayer Healthcare Llc |
針對活化蛋白c的人源化單克隆抗體及其用途
|
|
TWI632159B
(zh)
*
|
2013-02-08 |
2018-08-11 |
諾華公司 |
抗－ｉｌ－１７ａ抗體及其於治療自體免疫及發炎病症之用途
|
|
TW201444867A
(zh)
|
2013-03-08 |
2014-12-01 |
Lilly Co Eli |
抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
|
|
WO2014155278A2
(en)
|
2013-03-26 |
2014-10-02 |
Novartis Ag |
Methods of treating autoimmune diseases using il-17 antagonists
|
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US20150004133A1
(en)
*
|
2013-06-07 |
2015-01-01 |
The Regents Of The University Of California |
Compositions And Methods For Treating Steatohepatitis, Liver Fibrosis, and Hepatocellular Carcinoma (HCC)
|
|
US9603882B2
(en)
|
2013-08-13 |
2017-03-28 |
Industrial Technology Research Institute |
Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
|
|
WO2015022656A1
(en)
|
2013-08-15 |
2015-02-19 |
Novartis Ag |
Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
|
|
EP3072905B1
(en)
*
|
2013-11-18 |
2020-08-19 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Il-17a binding agent and uses thereof
|
|
EP3088000A4
(en)
*
|
2013-12-27 |
2017-08-09 |
Osaka University |
Vaccine targeting il-17a
|
|
DK3089994T3
(da)
*
|
2013-12-30 |
2022-07-04 |
Epimab Biotherapeutics Inc |
Fabs-in-tandem-immunglobulin og anvendelser deraf
|
|
WO2015127405A2
(en)
|
2014-02-21 |
2015-08-27 |
Genentech, Inc. |
Anti-il-13/il-17 bispecific antibodies and uses thereof
|
|
RU2577228C2
(ru)
*
|
2014-03-14 |
2016-03-10 |
Закрытое Акционерное Общество "Биокад" |
Анти-il-17-антитела, способ их получения и способ применения
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
SI3191120T1
(sl)
|
2014-09-10 |
2024-10-30 |
Novartis Ag |
Uporaba antagonistov IL-17 za zaviranje napredovanja strukturne poškodbe pri pacientih s psoriatičnim artritisom
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
EP3206711B1
(en)
|
2014-10-14 |
2023-05-31 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
|
CN108064235A
(zh)
|
2015-01-12 |
2018-05-22 |
阿菲博迪公司 |
Il-17a结合多肽
|
|
CN107407677B
(zh)
|
2015-01-28 |
2020-07-17 |
豪夫迈·罗氏有限公司 |
多发性硬化的基因表达标志和治疗
|
|
CN106336459B
(zh)
*
|
2015-07-13 |
2020-12-08 |
三生国健药业（上海）股份有限公司 |
抗人白细胞介素-17a单克隆抗体、其制备方法和应用
|
|
AU2016294332A1
(en)
|
2015-07-16 |
2017-11-30 |
Eli Lilly And Company |
Treatment of pruritus
|
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
EP3317301B1
(en)
|
2015-07-29 |
2021-04-07 |
Novartis AG |
Combination therapies comprising antibody molecules to lag-3
|
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
US11077187B2
(en)
|
2015-11-17 |
2021-08-03 |
Oklahoma Medical Research Foundation |
Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
AU2017214692B2
(en)
|
2016-02-06 |
2021-11-04 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
CN107488227A
(zh)
*
|
2016-06-12 |
2017-12-19 |
三生国健药业（上海）股份有限公司 |
抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
|
|
WO2017221174A1
(en)
|
2016-06-22 |
2017-12-28 |
Novartis Ag |
Methods of treating vitiligo using interleukin-17 (il-17) antibodies
|
|
JP2019521156A
(ja)
|
2016-07-19 |
2019-07-25 |
ノバルティス アーゲー |
Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
|
|
WO2018050028A1
(zh)
*
|
2016-09-14 |
2018-03-22 |
北京韩美药品有限公司 |
一种能够特异性地结合il-17a的抗体及其功能片段
|
|
JP2019505516A
(ja)
|
2016-11-28 |
2019-02-28 |
ノバルティス アーゲー |
インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
|
|
AR110873A1
(es)
|
2017-02-10 |
2019-05-08 |
Genentech Inc |
Anticuerpos contra triptasa, composiciones de estos y usos de estos
|
|
WO2018158741A1
(en)
|
2017-03-03 |
2018-09-07 |
Novartis Ag |
Psoriasis disease modification following long-term treatment with an il-17 antagonist
|
|
KR102321861B1
(ko)
*
|
2017-03-10 |
2021-11-05 |
쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 |
Il-17a 및 il-17f 모두에 대한 단일클론 항체 및 이의 용도
|
|
WO2018170488A1
(en)
*
|
2017-03-17 |
2018-09-20 |
Gilead Sciences, Inc. |
Method of purifying an antibody
|
|
TW201842933A
(zh)
|
2017-05-05 |
2018-12-16 |
瑞士商諾華公司 |
使用il-17拮抗劑選擇性治療氣喘的方法
|
|
EP3641813A4
(en)
|
2017-06-18 |
2021-04-21 |
Kindred Biosciences, Inc. |
IL17A ANTIBODIES AND ANTAGONISTS FOR USE IN VETERINARY MEDICINE
|
|
WO2019027828A1
(en)
|
2017-08-04 |
2019-02-07 |
Eli Lilly And Company |
DOSAGE SCHEME OF ANTI-IL-17 ANTIBODIES
|
|
WO2019040230A1
(en)
|
2017-08-23 |
2019-02-28 |
Eli Lilly And Company |
TREATMENT OF GENITAL PSORIASIS
|
|
RU2020117362A
(ru)
|
2017-11-02 |
2021-12-02 |
Новартис Аг |
Способы лечения тендинопатии с помощью антагонистов интерлейкина-17 (il-17)
|
|
KR102048475B1
(ko)
*
|
2017-11-10 |
2019-11-26 |
주식회사 와이바이오로직스 |
IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도
|
|
EP3712170A4
(en)
*
|
2017-11-10 |
2022-03-02 |
Jiangsu Hengrui Medicine Co., Ltd. |
CD96 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
|
|
US20200277369A1
(en)
|
2017-11-20 |
2020-09-03 |
Novartis Ag |
Method of treating hidradentitis suppurativa with il-17 antagonists
|
|
JP2021509009A
(ja)
|
2017-11-30 |
2021-03-18 |
ノバルティス アーゲー |
Ｂｃｍａターゲティングキメラ抗原受容体及びその使用
|
|
US11619832B2
(en)
|
2018-03-08 |
2023-04-04 |
Coopervision International Limited |
Identification of contact lens wearers predisposed to contact lens discomfort
|
|
JP7368453B2
(ja)
|
2018-05-03 |
2023-10-24 |
シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド |
Ｐｄ－１およびｌａｇ－３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質
|
|
US12110323B2
(en)
|
2018-05-17 |
2024-10-08 |
Jiangsu Qyuns Therapeutics Co., Ltd. |
Anti-human interleukin 17A monoclonal antibody and application thereof
|
|
EP3802611A2
(en)
|
2018-06-01 |
2021-04-14 |
Novartis AG |
Binding molecules against bcma and uses thereof
|
|
GB201810327D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicycletx Ltd |
Peptide ligands for binding to IL-17
|
|
JP7504871B2
(ja)
|
2018-08-29 |
2024-06-24 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
関節リウマチを有する対象を治療するための方法および組成物
|
|
EP3856772A1
(en)
|
2018-09-25 |
2021-08-04 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
|
|
CN111018974B
(zh)
*
|
2018-10-10 |
2022-04-01 |
东莞市朋志生物科技有限公司 |
一种抗人心肌肌钙蛋白i的重组抗体
|
|
GB201820316D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for IL-17
|
|
CN109369806B
(zh)
*
|
2019-01-14 |
2019-04-19 |
迈威(上海)生物科技有限公司 |
苏金单抗制品中半胱氨酸化变异体的去除方法
|
|
AU2020216978B2
(en)
|
2019-01-31 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
|
|
EP3689907A1
(en)
|
2019-01-31 |
2020-08-05 |
Numab Therapeutics AG |
Antibodies targeting il-17a and methods of use thereof
|
|
JP7525499B2
(ja)
|
2019-01-31 |
2024-07-30 |
ヌマブ セラピューティクス アクチェンゲゼルシャフト |
ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
|
|
JP7266108B2
(ja)
*
|
2019-02-18 |
2023-04-27 |
イーライ リリー アンド カンパニー |
治療用抗体製剤
|
|
MA55760A
(fr)
|
2019-04-24 |
2022-03-02 |
Regeneron Pharma |
Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde
|
|
KR102400401B1
(ko)
*
|
2019-05-22 |
2022-05-24 |
(주)셀인바이오 |
항염증 펩타이드 및 항염증 조성물
|
|
BR112021024445A2
(pt)
|
2019-06-04 |
2022-02-15 |
Regeneron Pharma |
Composições e métodos para tratamento de dor em indivíduos com artrite reumatoide
|
|
CN114286827B
(zh)
|
2019-07-26 |
2024-01-12 |
神州细胞工程有限公司 |
人源化抗il17a抗体及其应用
|
|
CN114127108A
(zh)
|
2019-07-30 |
2022-03-01 |
江苏恒瑞医药股份有限公司 |
Il-17拮抗剂治疗自身免疫疾病的方法
|
|
CN114981302A
(zh)
|
2019-09-20 |
2022-08-30 |
诺华股份有限公司 |
使用白细胞介素-17(il-17)拮抗剂治疗自身免疫性疾病的方法
|
|
CA3154522A1
(en)
|
2019-10-15 |
2021-04-22 |
Christopher Carl Frye |
Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
|
|
CA3161801A1
(en)
|
2019-11-19 |
2021-05-27 |
Novartis Ag |
Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
|
|
IL293354A
(en)
|
2019-12-06 |
2022-07-01 |
Novartis Ag |
Methods of treating lichen planus using interleukin-17 (il-17) antagonists
|
|
GB201918557D0
(en)
|
2019-12-16 |
2020-01-29 |
Bicycle Tx Ltd |
Bicyclic peptide ligands specific for IL-17
|
|
WO2021123767A1
(en)
|
2019-12-16 |
2021-06-24 |
Bicycletx Limited |
Bicyclic peptide ligands specific for il-17
|
|
GB201918559D0
(en)
|
2019-12-16 |
2020-01-29 |
Bicycle Tx Ltd |
Bicyclic peptide ligands specific for IL-17
|
|
GB201918558D0
(en)
|
2019-12-16 |
2020-01-29 |
Bicycle Tx Ltd |
Bicyclic peptide ligands specific for IL-17
|
|
GB201919062D0
(en)
*
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
|
KR20230016220A
(ko)
|
2020-05-27 |
2023-02-01 |
사노피 |
Il-17a 조절제
|
|
US20230286943A1
(en)
|
2020-05-27 |
2023-09-14 |
Sanofi |
Il-17a modulators
|
|
EP4168117A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists
|
|
MX2023005353A
(es)
|
2020-11-06 |
2023-05-22 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas.
|
|
CN115746132B
(zh)
*
|
2021-09-03 |
2023-09-08 |
三优生物医药(上海)有限公司 |
抗il-17a抗体及其用途
|
|
IT202100023816A1
(it)
*
|
2021-09-16 |
2023-03-16 |
Takis S R L |
Anticorpo contro SARS-CoV-2 e suoi usi in campo medico.
|
|
CN113896793B
(zh)
*
|
2021-09-30 |
2023-05-26 |
港科鹏禾生物(苏州)有限公司 |
一种抗人il-17rc的单克隆抗体及其应用
|
|
CA3253618A1
(en)
|
2022-05-16 |
2023-11-23 |
Novartis Ag |
METHODS FOR TREATMENT OF GIANT CELL ARTERITIS USING INTERLEUKIN-17 (IL-17) ANTAGONISTS
|
|
EP4525914A1
(en)
|
2022-05-18 |
2025-03-26 |
Novartis AG |
Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
|
|
AU2023390968A1
(en)
|
2022-12-09 |
2025-07-24 |
Sanofi |
Therapeutic compounds
|
|
WO2025083549A1
(en)
|
2023-10-16 |
2025-04-24 |
Sun Pharma Advanced Research Company Limited |
Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
|
|
US20250171427A1
(en)
|
2023-11-17 |
2025-05-29 |
Sanofi |
Therapeutic compounds
|
|
WO2025248073A1
(en)
|
2024-05-30 |
2025-12-04 |
Sanofi |
Therapeutic compounds
|
|
CN120249218A
(zh)
*
|
2024-10-15 |
2025-07-04 |
武汉纺织大学 |
一种分泌抗微纳塑料广谱性单克隆抗体的杂交瘤细胞株及其应用
|